The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

B. Grellier, et al.
ESMO-AI 2025
Abstract available on ESMO-AI website – Download the abstract – Download the Poster